November 30, 2022 03:55 PM EST

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says

Zachary Brennan

Senior Editor

The FDA on Wednesday announced that Eli Lilly’s Covid-19 drug bebtelovimab is no longer authorized to treat Covid-19 because of the rising numbers of two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

US drugs rely heavily on ingredients made overseas, new report shows

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Lil­ly's Covid-19 mAb no longer au­tho­rized due to Omi­cron sub­vari­ants, FDA says

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says